Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors

NCT07071103 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Radiotherapy
Metastatic Solid Cancers
Immune Checkpoint Blockade
Esophageal Neoplasms Malignant
Lung Neoplasm Malignant
Drug Resistance

Interventions

RADIATION: Low-dose radiotherapy to the intestine (ILDR)
DRUG: PD-1/PD-L1 monoclonal antibodies

Sponsor

Chuangzhen Chen